Intra-abdominal: Review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue SUPPL. 2, 2004, Pages

  Goldstein, Ellie J C ^a,c   Snydman, David R ^b  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anaerobes; Bacteriology; Bacteroides fragilis; Carbapenems; Intra abdominal

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; TROVAFLOXACIN; UNINDEXED DRUG; ANTIINFECTIVE AGENT; BETA LACTAM; LACTAM; CEFTAZIDIME; CEFTIZOXIME; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES VULGATUS; CLINICAL TRIAL; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; REVIEW; SPECIES DIFFERENCE; TREATMENT FAILURE; VEIN DISEASE; ABDOMEN; ABDOMINAL ABSCESS; ADOLESCENT; ADULT; AGED; ANAEROBIC BACTERIUM; ANIMAL; ARTICLE; BACTERIAL INFECTION; COMMUNICABLE DISEASE; DRUG EFFECT; FEMALE; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; RAT; AEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; BACTERIOLOGY; DRUG TOLERABILITY; INJECTION SITE IRRITATION; INTESTINE FLORA; NONHUMAN; SURGICAL DRAINAGE;

ABDOMEN; ABDOMINAL ABSCESS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; BETA-LACTAMS; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; LACTAMS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RATS;

EID: 3042645804     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh201     Document Type: Review

References (46)

1. Onderdonk, A. B., Cisneros, R. L., Finberg, R. et al. (1990). Animal model system for studying virulence of host response to Bacteroides fragilis. Reviews of Infectious Diseases 12, Suppl. 1, S169-77.
2. Jousimies-Somer, H. R., Summanen, P., Citron, D. et al. (2002). Anaerobic Bacteriology Manual, 6th edn. Star Publishing Company, Belmont, CA, USA.
3. Montravers, P., Gauzit, R., Muller, C. et al. (1996). Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clinical Infectious Diseases 23, 486-94.
4. Roehrborn, A., Thomas, L., Potreck, O. et al. (2001). The microbiology of postoperative peritonitis. Clinical Infectious Diseases 33, 1513-9.
5. Koehler, J., Dorso, K. L., Young, K. et al. (1999). In vitro activities of the potent, broad-spectrum carbapenem MK-0826 [L-749 345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrobial Agents and Chemotherapy 43, 1170-6.
6. Gill, C. J., Jackson, J. J., Gerckens, L. S. et al. (1998). In vitro activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-748 345). Antimicrobial Agents and Chemotherapy 42, 1996-2001.
7. Goldstein, E. J. C., Citron, D. M., Merriam, C. V. et al. (2000). Activity of ertapenem [MK-0826] against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrobial Agents and Chemotherapy 44, 2389-94.
8. Pelak, B. A., Woods, G. L., Teppler, H. et al. (2002). Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. Journal of Chemotherapy 14, 227-33.
9. Solomkin, J. S., Yellin, A. E., Rotstein, O. D. et al. (2003). Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double blind, randomized comparative Phase III trial of ertapenem vs piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery 237, 235-45.
10. Yellin, A. E., Hassett, J. M., Fernandez, A. et al (2002). Ertapenem monotherapy versus combined therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. International Journal of Antimicrobial Agents 20, 165-73.
11. Bennion, R. S., Baron, E. J., Thompson, J. E. et al. (1990). The bacteriology of gangrenous and perforated appendicitis - revisited. Annals of Surgery 211, 155-71.
12. Bennion, R. S., Thompson, J. E., Baron, E. J. et al. (1990). Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. Clinical Therapeutics 12, Suppl. C, 31-44.
13. Baron, E. J., Bennion, R., Thompson, J. et al. (1992). A microbiological comparison between acute and complicated appendicitis. Clinical Infectious Diseases 14, 227-31.
14. Goldstein, E. J. C. & Citron, D. M. (1998). Bacteroides fragilis group: annual incidence, epidemiology, and comparative in vitro susceptibility to cefoxitin, cefotetan, cefmetazole, and ceftizoxime against recent community acquired isolates. Journal of Clinical Microbiology 26, 2361-6.
15. Brook, I. (1980). Bacterial studies of peritoneal cavity and postoperative surgical wound drainage following perforated appendix in children. Annals of Surgery 192, 208-12.
16. Rosenblat, J. E. & Brook, I. (1993). Clinical relevance of susceptibility testing of anaerobic bacteria. Clinical Infectious Diseases 16, Suppl. 4, S446-8.
17. Aldridge, K. E. & Sanders, C. V. (1987). Antibiotic- and method-dependent variation in susceptibility testing results of Bacteroides fragilis group isolates. Journal of Clinical Microbiology 25, 2317-21.
18. National Committee for Clinical Laboratory Standards. (1997). Methods For Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Fourth Edition: Approved Standard M11-A4. NCCLS, Villanova, PA, USA.
19. Citron, D. M., Ostovari, M. I., Karlsson, A. et al. (1991). Evaluation of the E test for susceptibility testing of anaerobic bacteria. Journal of Clinical Microbiology 29, 2197-203.
20. Goldstein, E. J. C., Citron, D. M., Goldman, R. J. et al. (1995). United States hospital survey of anaerobic culture and susceptibility methods II. Anaerobe 1, 309-14.
21. Cuchural, G. J., Jr, Tally, F. P., Jacobus, N. V. et al. (1988). Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrobial Agents and Chemotherapy 32, 717-22.
22. Snydman, D. R., Jacobus, N. V., McDermott, L. et al. (1999). Multi-center study of in-vitro susceptibility of the Bacteroides fragilis group, 1995-1996, with comparison of resistance trends from 1990-1996. Antimicrobial Agents and Chemotherapy 43, 2417-22.
23. Goldstein, E. J. C. (1996). Anaerobic bacteremia. Clinical Infectious Diseases 23, Suppl. 1, 97-101.
24. Redondo, M. C., Arbo, M. D. J., Grindlinger, J. et al. (1995). Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clinical Infectious Diseases 20, 1492-6.
25. Tally, F. P., Cuchural, G. J., Jacobus, N. V. et al. (1983). Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrobial Agents and Chemotherapy 23, 536-40.
26. Tally, F. P., Snydman, D. R., Gorbach, S. L. et al. (1979). Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. Journal of Infectious Diseases 139, 83-8.
27. Golan, Y., Jacobus, N. V., McDermott, L. A. et al. (2001). The changing epidemiology of Bacteroides species (BSp) infections in the US. In Program and Abstracts of the Forty-first International Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract, K-1209, p. 412. American Society for Microbiology, Washington, DC, USA.
28. Snydman, D. R., Cuchural, G. J., McDermott, L. et al. (1992). Correlation of various in-vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrobial Agents and Chemotherapy 36, 540-4.
29. Nguyen, M. H., Yu, V. L., Morris, A. J. et al. (2000). Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clinical Infectious Diseases 30, 870-6.
30. Snydman, D. R., Jacobus, N. V., McDermott, L. A. et al. (2002). National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clinical Infectious Diseases 35, S126-34.
31. Snydman, D. R., Jacobus, N. V., McDermott, L. A. et al. (2002). Analysis of in vitro activity of newer quinolones against Bacteroides group organisms. Antimicrobial Agents and Chemotherapy 46, 3276-9.
32. Betriu, C., Sanchez, A., Palau, M. L. et al. (2001). In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides; fragilis group strains. Antimicrobial Agents and Chemotherapy 45, 2372-4.
33. Mazuski, J. E., Sawyer, R. G., Nathens, A. B. et al. (2002). The surgical infection society guidelines on antimicrobial therapy for intraabdominal infections: an executive summary. Surgical Infections 3, 161-73.
34. Onderdonk, A. B., Weinstein, W. M., Sullivan, N. M. et al. (1974). Experimental intra-abdominal abscesses in rats: quantitative bacteriology of infected animals. Infection and Immunity 10, 1256-9.
35. Weinstein, W. M., Onderdonk, A. B., Bartlett, J. G. et al. (1974). Experimental intra-abdominal abscesses in rats: development of an experimental model. Infection and Immunity 10, 1250-5.
36. Onderdonk, A. B., Bartlett, J. G., Louie, T. et al. (1976). Microbial synergy in experimental intra-abdominal abscess. Infection and Immunity 13, 22-6.
37. Weinstein, W. M., Onderdonk, A. B., Bartlett, J. G. et al. (1975). Treatment of experimental intraadominal sepsis in rats. Journal of Infectious Diseases 132, 282-6.
38. Louie, T. J., Onderdonk, A. B., Gorbach, S. L. et al. (1977). Therapy for experimental intraabdominal sepsis: comparison of four cephalosporins with clindamycin plus gentamicin. Journal of Infectious Diseases 135, Suppl., S18-22.
39. Onderdonk, A. B., Shapiro, M. E., Finberg, R. W. et al. (1984). Use of a model of intraabdominal sepsis for studies of the pathogenicity of Bacteroides fragilis. Reviews of Infectious Diseases 6, Suppl. 1, S91-5.
40. Appleman, M. D., Citron, D. M., Heseltine, P. N. R. et al. (1998). In vitro activity of MK0826 compared to imipenem, ceftriaxone, and metronidazole against anaerobic bacteria isolated from intra-abdominal infections. In Program and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 1998. Abstract F-43, p. 244. American Society for Microbiology, Washington, DC, USA.
41. Fuchs, P. C., Barry, A. L. & Brown, S. D. (1999). In vitro antimicrobial activity of a carbapenem, MK-0826 [L-749 345] and provisional interpretive criteria for disc tests. Journal of Antimicrobial Chemotherapy 43, 703-6.
42. Friedland, I. R., Isaacs, R., Mixson, L. A. et al. (2002). Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagnostic Microbiology and Infectious Disease 43, 61-4.
43. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard. M7-A5. NCCLS, Villanova, PA, USA.
44. Baron, E. J., Strong, C. A., McTeague, M. et al. (1995). Survival of anaerobes in original specimens transported by overnight mail services. Clinical Infectious Diseases 20, Suppl. 2, 174-7.
45. Talan, D. A., Citron, D. M., Abrahamian, F. A. et al. (1999). The bacteriology and management of dog and cat bite wound infections presenting to emergency departments. New England Journal of Medicine 340, 85-92.
46. National Committee for Clinical Laboratory Standards. (2001). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Fifth Edition: Approved Standard M11-A5. NCCLS, Villanova, PA, USA.